Application of CD34 expression combined with three-phase dynamic contrast-enhanced computed tomography scanning in preoperative staging of gastric cancer

Table 6 Univariate analysis

		Metastatic group (n = 69)	Non-metastatic group (n = 37)	χ2/t	P value
Age (yr)		59.3 ± 7.6	54.2 ± 7.2	3.353	0.001
Gender				0.687	0.407
	Male	51 (73.91)	30 (81.08)
	Female	18 (26.09)	7 (18.92)
Tumor length (cm)		3.73 ± 1.25	5.72 ± 1.75	6.124	< 0.001
Pathological T staging				21.296	< 0.001
	T1	7 (10.14)	18 (48.65)
	T2	19 (27.54)	9 (24.32)
	T3	28 (40.58)	6 (16.22)
	T4	15 (21.74)	4 (10.81)
Tissue typing				6.226	0.046
	Adenocarcinoma	49 (71.01)	34 (91.89)
	Signet-ring cell carcinoma	15 (21.74)	2 (5.41)
	Neuroendocrine carcinoma	5 (7.25)	1 (2.70)
Degree of differentiation				8.117	0.017
	High differentiation (n = 32)	15 (21.74)	17 (45.95)
	Moderate differentiation (n = 55)	38 (55.07)	17 (45.95)
	Low differentiation (n = 19)	16 (23.19)	3 (8.11)
Expression of CD34-labelled MVD		84.57 ± 17.83	47.81 ± 14.93	10.686	< 0.001

MVD: Microvessel density.